PMID- 30650098
OWN - NLM
STAT- MEDLINE
DCOM- 20190930
LR  - 20221207
IS  - 1932-6203 (Electronic)
IS  - 1932-6203 (Linking)
VI  - 14
IP  - 1
DP  - 2019
TI  - Human leukocyte antigen and demographic characteristics in Chinese patients with 
      active peripheral type psoriatic arthritis who had inadequate response to 
      conventional disease-modifying antirheumatic drugs in a single dermatologic 
      clinic.
PG  - e0210076
LID - 10.1371/journal.pone.0210076 [doi]
LID - e0210076
AB  - BACKGROUND: Correlation between severity of psoriasis and psoriatic arthritis 
      (PsA) is inconsistent. Also, human leukocyte antigen (HLA)-Cw6 was found to be 
      underrepresented in severe psoriasis who failed conventional systemic therapies, 
      but the effect of HLA polymorphism on PsA severity needs to be confirmed. 
      OBJECTIVES: To describe the severity of psoriasis, demographic features and HLA 
      polymorphism among Chinese patients with active peripheral type PsA who had 
      inadequate response to conventional disease-modifying antirheumatic drugs. 
      METHODS: We included all patients with PsA who had at least 3 tender and swollen 
      peripheral joints despite at least two conventional non-biologic treatments in 
      our clinic. Demographic results were compared with global pivotal studies of 
      biologics for PsA. HLA-Cw and HLA-DRB1 genotyping was also analyzed. RESULTS: We 
      identified 60 patients who met our inclusion criteria. The male to female ratio 
      was 1.31:1. The majority of patients presented with psoriasis first (81.7%). The 
      mean interval between psoriasis and PsA was 7.2 +/- 8.1 years (mean +/- SD). The 
      baseline number of tender and swollen joints was 14.9 +/- 10.7 and 11.3 +/-10.2, 
      respectively. In total, 41.7% subjects had more than 3% body surface area 
      involvement of psoriasis. Genotyping of HLA-Cw and HLA-DRB1 was performed in 47 
      subjects. HLA-Cw*0702 was the most frequent allele (29.8%), followed by HLA-Cw*01 
      (26.6%). The frequency of HLA-Cw*0602 allele was similar to normal population. 
      The most frequent HLA-DRB1 allele was HLA-DRB1*04 (20.2%), followed by 
      HLA-DRB1*08 (16.0%). No cases carrying HLA-DRB1*13 were detected. CONCLUSIONS: 
      Compared with Western population, our patients had less psoriasis and PsA burden. 
      The frequencies of HLA-Cw*06, HLA-Cw*12, and HLA-DRB1*07 were not increased. In 
      contrast, HLA-Cw*0702 and HLA-DRB1*08 allele frequencies were increased compared 
      with psoriasis patients and normal population in Taiwan. Future studies are still 
      needed to characterize the demographic and genetic features of high need PsA 
      patients.
FAU - Sin, Chi-Zai
AU  - Sin CZ
AUID- ORCID: 0000-0002-0597-6964
AD  - Department of Dermatology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, Taipei, Taiwan.
FAU - Wang, Ting-Shun
AU  - Wang TS
AD  - Department of Dermatology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, Taipei, Taiwan.
AD  - Division of Dermatology, Chung Shan Medical University Hospital, Taichung, 
      Taiwan.
FAU - Chiu, Hsien-Yi
AU  - Chiu HY
AD  - Department of Dermatology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, Taipei, Taiwan.
AD  - Department of Dermatology, Hsin-Chu Branch, National Taiwan University Hospital, 
      Hsin-Chu, Taiwan.
FAU - Tsai, Tsen-Fang
AU  - Tsai TF
AUID- ORCID: 0000-0002-1498-1474
AD  - Department of Dermatology, National Taiwan University Hospital and National 
      Taiwan University College of Medicine, Taipei, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20190116
PL  - United States
TA  - PLoS One
JT  - PloS one
JID - 101285081
RN  - 0 (Antirheumatic Agents)
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Alleles
MH  - Antirheumatic Agents/*therapeutic use
MH  - Arthritis, Psoriatic/*drug therapy/ethnology/genetics
MH  - Asian People/genetics
MH  - Female
MH  - Gene Frequency
MH  - Genetic Predisposition to Disease/ethnology/*genetics
MH  - Genotype
MH  - HLA Antigens/*genetics
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - *Polymorphism, Genetic
MH  - Psoriasis/drug therapy/ethnology/genetics
MH  - Skin/drug effects/metabolism/pathology
MH  - Taiwan
PMC - PMC6334904
COIS- T-F Tsai has conducted clinical trials or received honoraria for serving as a 
      consultant for AbbVie, Boehringer Ingelheim, Celgene, Eli Lilly, Galderma, 
      GSK-Stiefel, Janssen-Cilag, Leo Pharma, Merck, Novartis Pharmaceuticals, Pfizer 
      Inc., and Serono International SA (now Merck Serono International). Dr. Chiu has 
      received speaking fees from AbbVie, Janssen-Cilag Pharmaceutical, and Pfizer. Dr. 
      Wang has received speaking fee from AbbVie, Pfizer, Novartis International AG, 
      and Janssen-Cilag Pharmaceuticals. This does not alter our adherence to PLOS ONE 
      policies on sharing data and materials.
EDAT- 2019/01/17 06:00
MHDA- 2019/10/01 06:00
PMCR- 2019/01/16
CRDT- 2019/01/17 06:00
PHST- 2018/06/23 00:00 [received]
PHST- 2018/11/10 00:00 [accepted]
PHST- 2019/01/17 06:00 [entrez]
PHST- 2019/01/17 06:00 [pubmed]
PHST- 2019/10/01 06:00 [medline]
PHST- 2019/01/16 00:00 [pmc-release]
AID - PONE-D-18-18768 [pii]
AID - 10.1371/journal.pone.0210076 [doi]
PST - epublish
SO  - PLoS One. 2019 Jan 16;14(1):e0210076. doi: 10.1371/journal.pone.0210076. 
      eCollection 2019.